| cDNA | Complementary DNA |
| CI | Confidence intervals |
| CT | Computed tomography |
| Ct | Cycle threshold |
| DCR | Disease Control Rate |
| ECOG | Eastern Cooperative Oncology Group |
| EDTA | Ethylenediaminetetraacetic acid |
| EMT | Epithelial to Mesenchymal Transition |
| HR | Hazard ratio |
| ICIs | Immune Checkpoint Inhibitors |
| MDSCs | Myeloid-Derived Suppressor Cells |
| miRNAs | microRNAs |
| MRI | Magnetic resonance imaging |
| NK | Natural killer cells |
| non-SqCC | non-Squamous |
| NSCLC | Non-Small Cell Lung Cancer |
| ORR | Objective Response Rate |
| OS | Overall survival |
| PD | Progression disease |
| PDDC | Prolonged Duration of Disease Control |
| PFS | Progression-free survival |
| PR | Partial response |
| PS | Performance status |
| RT-qPCR | Real-time quantitative polymerase chain reaction |
| SD | Stable disease |
| SqCC | Squamous |
| TILs | Tumor-infiltrating lymphocytes |
| TME | Tumor microenvironment |
| TNBC | Triple-negative breast cancer |
| Tregs | T regulatory cells |